Chimin(SH:603222) Mei Ri Jing Ji Xin Wen·2025-08-21 10:41Core Viewpoint - Jimin Health (603222.SH) reported a significant decline in revenue and a shift from profit to loss in its 2025 semi-annual report, alongside a negative cash flow from operating activities [2][4][6]. Financial Performance - The company achieved a revenue of 366.45 million yuan, a year-on-year decrease of 21.30% [4][5]. - The net profit attributable to shareholders was -52.70 million yuan, compared to a profit of 25.44 million yuan in the same period last year, marking a 307.10% decline [4][5]. - The net cash flow from operating activities was approximately -36.10 million yuan, a significant drop from 41.73 million yuan in the previous year, reflecting a 186.50% decrease [6]. - The weighted average return on net assets decreased by 5.24 percentage points to -3.63% [6]. Stock Performance - Jimin Health's stock price saw a cumulative increase of 53.78% from August 13 to August 19, 2025, before experiencing a significant drop on August 21, where it fell nearly 4% [2][3]. Operational Challenges - The decline in revenue was attributed to a 39.58% drop in export income from safety syringes due to U.S. tariff policies and a staggering 92.24% decrease in domestic sales of pre-filled catheter flushing devices and safety syringes, linked to a scandal involving a former vice president [8][9]. - The company is currently involved in legal issues related to the forgery of company seals by its former vice president, which has resulted in 19 lawsuits with a total amount in dispute of 73.06 million yuan [8][9].